CYFRA21-1、CA125与CEA联检对非小细胞肺癌诊断的临床应用

目的:探讨CYFRA21-1、CA125、CEA单项及联检对小细胞肺癌的临床应用价值.方法:采用化学发光法、放射免疫分析联检我院从2000年元月～2007年3月由病理证实的非小细胞肺癌患者171例血清CYFRA21-1、CA125、CEA值.结果:CYFRA21-1在鳞癌中阳性率最高为54.3%,CA125、CEA在腺癌中阳性率最高,分别为59.8%、49.0%.三项联检总阳性率明显升高为80.7%.结论:联检CYFRA21-1、CA125和CEA可起到互补作用,从而明显提高非小细胞肺癌的阳性检出率,且肿瘤的阳性检出率随病情的进展而升高.

Clinical Diagnostic Application of Combined Determination of CYFRA21 -1, CA125 and CEA for Non -Small Cell Lung Carcinoma

Objective To investigate the clinical diagnostic usefulness of determination of dumor markers CYFRA21-1,CA125 and CEA for non-small cell lung carcinoma.Methods Serum CYFRA21-1(with IRMA) and CA125,CEA(with CLIA) levels were determined in 171 patients with non-small cell lung carcinoma.Results Positive rate of CYFRA21-1 was highest in patients with squamous cell carcinoma(54.3%),while postive rate of CA125 and CEA was higher in patients with adenocarcinoma(59.8%,49.0% respectively).Combined determination of the three markers increased the over all positive rate to 80.7% for the whole non-small cell lung cancer patients population.Conclusion Combined determination of the markers is complementary with significant enhancement of the diagnostic positive rate for non-small cell lung carcinoma.The positive rate increases along with the progression of the disease.